|1.||Qadri, Firdausi: 4 articles (12/2009 - 08/2005)|
|2.||Killeen, Kevin P: 4 articles (12/2007 - 04/2002)|
|3.||Kochi, Sims K: 2 articles (12/2007 - 04/2002)|
|4.||Chowdhury, Mohiul I: 2 articles (01/2007 - 08/2005)|
|5.||Sack, David A: 2 articles (01/2007 - 08/2005)|
|6.||Seidlein, Lorenz V: 2 articles (01/2007 - 08/2005)|
|7.||Clemens, John D: 2 articles (01/2007 - 08/2005)|
|8.||Begum, Yasmin A: 2 articles (01/2007 - 08/2005)|
|9.||Park, Eunsik: 2 articles (01/2007 - 08/2005)|
|10.||Ahmed, Tanvir: 2 articles (01/2007 - 08/2005)|
12/01/2009 - "Phase III studies are being targeted to determine the protective efficacy of CholeraGarde and for further development of a single-dose vaccine that will protect infants and also other age groups from endemic and epidemic cholera."
04/01/2002 - "Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine."
12/12/2007 - "Peru-15 is an oral, single-dose, live-attenuated cholera vaccine candidate that has been investigated in several clinical trials (n>400 subjects) and was proven well tolerated, immunogenic, and efficacious. "
08/15/2005 - "The safety and immunogenicity of this Peru-15 vaccine candidate indicates the usefulness of future studies in Bangladesh, where cholera is endemic."
08/15/2005 - "Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh."
10/01/1995 - "Two Peru-15 vaccinees developed diarrhea, 1 with < 0.3 L and 1 with approximately 1.0 L; this latter volunteer had not developed a significant vibriocidal immune response to vaccination. "
04/01/2002 - "We wished to determine whether a single oral dose of Peru-15 was safe and immunogenic and whether it would provide significant protection against moderate and severe diarrhea in a randomized, double-blind, placebo-controlled human volunteer cholera challenge model. "
04/01/2002 - "Peru-15 is a well-tolerated and immunogenic oral cholera vaccine that affords protective efficacy against life-threatening cholera diarrhea in a human volunteer challenge model. "
04/01/2007 - "extract, capromorelin, CBP-501, cediranib, cetuximab, CHR-2797; Dapoxetine hydrochloride, degarelix acetate, desvenlafaxine succinate, dimethyl fumarate, dronedarone hydrochloride; Ecogramostim, eprodisate sodium; Falciparum merozoite protein-1/AS02A, fospropofol disodium; Gefitinib, glucarpidase, GTI-2040; Hepatitis C vaccine, HMR-4902, human proinsulin C-peptide, hyaluronic acid; Ipilimumab, ixabepilone; Lapatinib, lenalidomide, lestaurtinib, liposome encapsulated doxorubicin; Manidipine hydrochloride/delapril hydrochloride, metreleptin, MG-98, MGCD-0103, morphine glucuronide; Nebicapone; O6-benzylguanine, ofatumumab, olmesartan medoxomil/hydrochlorothiazide; PAN-811, pemetrexed disodium, perifosine, pertuzumab, Peru-15, pexelizumab, pirfenidone, pralatrexate, prasugrel; Quercetin; Rivaroxaban; Semaxanib, St. John's Wort extract; Ticagrelor, tomopenem, triplatin tetranitrate; Ulipristal acetate; Vandetanib, vatalanib succinate, vildagliptin; XK-469; ZT-1."
|4.||Succinic Acid (Succinate)
|7.||Morphine (MS Contin)
|10.||Hyaluronic Acid (Hyaluronan)